Meiji And Dong-A Start European Ustekinumab Trial
Dosing Of Phase I Subjects Underway
A Phase I study will compare the pharmacokinetics, safety and tolerability of Meiji and Dong-A’s DMB-3115 ustekinumab biosimilar candidate against Janssen’s Stelara reference psoriasis and Crohn’s disease brand.
